HRMY
Harmony Biosciences Holdings, Inc.
$41.52
+0.42
(+1.02%)
Mkt Cap
2.40B
Volume
973,307
52W Range
25.52-43.49
Sector
Healthcare
Beta
0.93
EPS (TTM)
3.13 USD
P/E Ratio
13.27
Revenue (TTM)
959.90M USD
Rev Growth (5Y)
+40.3%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
What we estimate one share is worth
$120.52
Undervalued
strong signal
65.5% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade
How strong & durable the business is
A-
Platform & Compounding FCF
85.5 / 100 composite
A platform business that compounds free cash flow — graded A–F vs. similar companies.
Company Description
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 868.45M | 714.73M | 582.02M | 437.86M | 305.44M | 159.74M | 6.00M | 0 |
| Net Income | 158.69M | 145.49M | 128.85M | 181.47M | 34.60M | (36.94M) | (151.98M) | (39.90M) |
| EPS | 2.76 | 2.56 | 2.17 | 3.07 | 0.60 | -1.12 | -2.94 | -1.42 |
| Free Cash Flow | 347.89M | 218.67M | 219.07M | 144.29M | 98.26M | (4.99M) | (75.58M) | (40.14M) |
| FCF / Share | 6.05 | 3.84 | 3.68 | 2.44 | 1.71 | -0.09 | -1.19 | -0.82 |
| Operating CF | 348.20M | 219.82M | 219.39M | 144.47M | 98.56M | (2.98M) | (75.44M) | (38.80M) |
| Total Assets | 1.27B | 999.20M | 811.45M | 673.87M | 433.44M | 427.07M | 106.70M | 89.28M |
| Total Debt | 239.58M | 181.41M | 193.57M | 191.65M | 195.74M | 194.25M | 97.95M | 324.20M |
| Cash & Equiv | 752.50M | 453.00M | 311.66M | 243.78M | 234.31M | 228.63M | 24.46M | 83.52M |
| Book Value | 870.22M | 659.15M | 466.99M | 402.84M | 186.51M | 97.18M | (11.59M) | 81.53M |
| Return on Equity | 0.18 | 0.22 | 0.28 | 0.45 | 0.19 | -0.38 | N/A | -0.49 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 261.28M | 215.39M | 243.78M | 239.46M | 200.49M | 184.73M | 201.27M | 186.04M | 172.81M | 154.62M | 168.41M | 160.27M |
| Net Income | 75.43M | 32.49M | 22.49M | 50.87M | 39.78M | 45.56M | 49.48M | 46.09M | 11.59M | 38.33M | 26.61M | 38.46M |
| EPS | 1.30 | 0.56 | 0.39 | 0.88 | 0.69 | 0.80 | 0.87 | 0.81 | 0.20 | 0.68 | 0.46 | 0.64 |
| Free Cash Flow | 92.43M | 27.76M | 126.04M | 108.66M | 79.32M | 33.86M | 75.05M | 70.50M | 41.98M | 31.14M | 76.56M | 63.10M |
| FCF / Share | 1.60 | 0.48 | 2.19 | 1.86 | 1.38 | 0.59 | 1.31 | 1.24 | 0.74 | 0.55 | 1.31 | 1.05 |
| Operating CF | 92.43M | 27.76M | 126.15M | 108.73M | 79.33M | 33.99M | 75.56M | 70.50M | 42.62M | 31.14M | 76.67M | 63.10M |
| Total Assets | 1.37B | 1.27B | 1.27B | 1.21B | 1.11B | 1.06B | 999.20M | 928.13M | 858.38M | 846.99M | 811.45M | 777.77M |
| Total Debt | 153.96M | 206.51M | 239.58M | 169.73M | 173.37M | 177.46M | 181.41M | 185.24M | 189.06M | 193.06M | 196.09M | 199.72M |
| Cash & Equiv | 549.77M | 589.40M | 752.50M | 647.00M | 546.05M | 489.00M | 453.00M | 387.37M | 317.30M | 332.98M | 311.66M | 324.60M |
| Book Value | 999.24M | 910.35M | 870.22M | 835.12M | 773.08M | 720.52M | 659.15M | 596.80M | 538.58M | 515.39M | 466.99M | 481.33M |
| Return on Equity | 0.08 | 0.04 | 0.03 | 0.06 | 0.05 | 0.06 | 0.08 | 0.08 | 0.02 | 0.07 | 0.06 | 0.08 |
HRMY News
Sonoma Pharmaceuticals (NASDAQ:SNOA) & Harmony Biosciences (NASDAQ:HRMY) Critical Analysis
Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report?
Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress
Canada Pension Plan Investment Board Takes $1.21 Million Position in Harmony Biosciences Holdings, Inc. $HRMY
Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference
Aurora Investment Counsel Invests $2.37 Million in Harmony Biosciences Holdings, Inc. $HRMY
Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline
Harmony Biosciences Holdings, Inc. $HRMY Position Raised by California State Teachers Retirement System
4 Healthcare Stocks to Watch as Defensive Demand Strengthens
4 Stocks Trading Near 52-Week High With More Upside Potential